Clinical Trials
172 trialsA Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Aura Biosciences
DP-04
AstraZeneca
ELEPHAS-02
Elephas
MERLIN_001
SkylineDx
TraveraRTGx
Travera Inc
UK-EnBiRiM
Pierre Fabre Ltd
NISSO
Sun Pharmaceutical Industries Limited
LEGIT_MC_EVCDA
AI Labs Group S.L
LegitHealth PH
AI Labs Group S.L
LegitHealthSAN
AI Labs Group S.L
Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers
AI Labs Group S.L
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Novartis
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
Aura Biosciences
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Amgen
SCORE
Natera, Inc.
CoMpass
Aura Biosciences
TavieSkin
Pierre Fabre Medicament
RPx
Replimune, Inc.
ELEPHAS-05
Elephas
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Pharmassist Ltd
LEAD Melanoma
Novartis
NEUTROFLOW
OncoHost Ltd.
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
Bristol-Myers Squibb
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics, Inc.
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Bristol-Myers Squibb
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
CASE
Regeneron Pharmaceuticals
PROPHETIC
OncoHost Ltd.
Skin Cancer
Nuvana Healthcare LTD
AIQ TRAQinform
AIQ Solutions
ORACLE
Guardant Health, Inc.
Pan-tumor MRD Study
Paradigm Health
DELFI-L101
Delfi Diagnostics Inc.
NICO
Bristol-Myers Squibb
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
Skin Analytics Limited
DermaFlow
HJN Sverige AB/Neko Health
Spectrum1
HJN Sverige AB/Neko Health
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Combi-EU
EuMelaReg gGmbH
Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC
EuMelaReg gGmbH
OCEANMIST
Pfizer
PREFER
Labcorp Corporation of America Holdings, Inc
COMO
Pamgene International B.V.
BEGIN
BostonGene
Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.
Xoft, Inc.
DermScan
Barco NV
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Pfizer
PIONEER
Mirai Medical
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
Bristol-Myers Squibb
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Momentum Data